INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42m ago
HOUSE PTR1m ago
SEC 13F1m ago
ROBINHOOD CHAIN1m ago
SEC FORM 4/Grant or awardVerified data

Cox Christopher Nixon reported ANRO

Director · Alto Neuroscience, Inc. · Alto Neuroscience, Inc. — Stock Option (right to buy)

Side
A
Value
—
Shares
11.0K
Price
—
Executed
May 12, 2026
Disclosed
May 14, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
May 12 executedMay 14, 2026 disclosed

ANRO · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ANRO

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    17
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M—
    55.0K sh
    		Oct 2, 2026Oct 5, 2026
    traded Oct 2, 2026
    		+3dSEC FORM 4

    Evidence

    20
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M$128K
    55.0K sh
    		Oct 2, 2026Oct 5, 2026
    traded Oct 2, 2026
    		+3dSEC FORM 4

    Evidence

    21
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M—
    56.5K sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    20
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M$57K
    24.1K sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M—
    54.4K sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    42
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Open-market sale
    		SELL$2.95M
    110.8K sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    24
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M$133K
    56.5K sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    24
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M$128K
    54.4K sh
    		Sep 29, 2026Oct 1, 2026
    traded Sep 29, 2026
    		+2dSEC FORM 4

    Evidence

    31
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Open-market sale
    		SELL$597K
    23.2K sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    13
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Option exercise
    		M—
    24.1K sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    17
    SC
    Smith Nicholas ConradPRESIDENT AND CFO
    ANROAlto Neuroscience, Inc.
    Open-market sale
    		SELL$24K
    886 sh
    		Sep 30, 2026Oct 1, 2026
    traded Sep 30, 2026
    		+1dSEC FORM 4

    Evidence

    24
    EA
    Etkin AmitDirector, PRESIDENT AND CEO
    ANROAlto Neuroscience, Inc.
    Gift
    		G—
    400.0K sh
    		May 14, 2026May 15, 2026
    traded May 14, 2026
    		+1dSEC FORM 4

    Evidence

    9
    YG
    York GwillDirector
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    11.0K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SR
    Sanchez RamiroDirector
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    11.0K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MH
    Manji HusseiniDirector
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    11.0K sh
    		May 12, 2026May 14, 2026
    traded May 12, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SC
    Smith Nicholas ConradCHIEF FINANCIAL OFFICER & CBO
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    200.0K sh
    		Feb 11, 2026Feb 13, 2026
    traded Feb 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    SA
    Savitz AdamCHIEF MEDICAL OFFICER
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    124.0K sh
    		Feb 11, 2026Feb 13, 2026
    traded Feb 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    HC
    Hanley Jr. Michael ConickCHIEF OPERATING OFFICER
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    131.0K sh
    		Feb 11, 2026Feb 13, 2026
    traded Feb 11, 2026
    		+2dSEC FORM 4

    Evidence

    9
    EA
    Etkin AmitDirector, PRESIDENT AND CEO
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A—
    306.0K sh
    		Feb 11, 2026Feb 13, 2026
    traded Feb 11, 2026
    		+2dSEC FORM 4

    Evidence

    12
    YG
    York GwillDirector
    ANROAlto Neuroscience, Inc.
    Grant or award
    		A$62K
    5,243 sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002008212-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 12, 2026
    Published
    May 14, 2026
    Ingested by INSIDER
    Nov 5, 03:58 UTC
    Last re-read
    Nov 5, 03:58 UTC

    Extracted facts

    Filer
    Cox Christopher Nixon
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Alto Neuroscience, Inc. — Stock Option (right to buy)
    Ticker
    ANRO
    Shares
    11.0K
    Price per share
    $0
    Execution date (reported)
    May 12, 2026
    Owned after transaction
    11.0K shares
    Days from execution to publication
    2

    What this establishes

    Cox Christopher Nixon filed this Form 4 reporting a grant or award of ANRO on May 12, 2026. It became public on May 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Cox Christopher Nixoncik:0002008212
    Issuer
    Alto Neuroscience, Inc.cik:0001999480

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.